Kisspeptin-10

A legitimate endocrine research tool with human physiologic studies. Not a lifestyle peptide. Fertility-medicine development (including longer analogs) is the serious path; gray-market Kp-10 is not that path.

Kisspeptin is the upstream peptide that stimulates GnRH neurons. Kp-10 is a short agonist used in research to probe the HPG axis: LH/FSH pulses, fertility work-ups, and experimental reproductive therapeutics.

Dhillo and others have published human infusion studies showing LH secretion in healthy volunteers and some hypogonadal states. Diagnostic and therapeutic programs are ongoing in specialist centers. Not a consumer evidence base.

Not FDA-approved as a consumer or general endocrine drug. Hospital/research use. Related analogs are in development.

A specialist/research tool. Human infusion studies happen in endocrine research units. FDA lists kisspeptin-10 in Category 2 for 503A compounding (immunogenicity and characterization concerns, insufficient safety information for proposed routes). It is not a consumer fertility peptide.

Same four pathways as the Sourcing guide.

Covered only as part of a work-up or trial in a specialist setting — not as a self-pay peptide.

Sold to men's-health and fertility forums as Kp-10. A bolus from a research vial is not Dhillo's infusion protocol.

Strand does not list vendors. See the grey market.

HPG-axis perturbation can disrupt menstrual cycles, spermatogenesis timing, and mood. Pregnancy is an obvious exclusion. Unregulated bolus use is not a fertility protocol.

• Still Category 2 at FDA for compounding.
• HPG-axis perturbation can disrupt cycles, spermatogenesis timing, and mood.
• Pregnancy is an exclusion. Unregulated bolus use is not fertility care.

• Dhillo et al. · 2005 · J Clin Endocrinol Metab

  Kisspeptin-54 stimulates the hypothalamic-pituitary-gonadal axis in human males. PMID 16234307.

• FDA Category 2

  Kisspeptin-10 — immunogenicity and insufficient safety information for proposed compounding routes.